Glioblastoma Driver Mutations Appear Long Before Diagnosis
By LabMedica International staff writers Posted on 03 Apr 2019 |
Image: A diagram of evolutionary trajectories of IDH-WT glioblastomas revealing a common path of early tumorigenesis instigated years ahead of initial diagnosis (Photo courtesy of German Cancer Research Center).
Glioblastomas are the most common high-grade (cancerous) primary brain tumor in adults. They can also occur, rarely, in children. Glioblastomas belong to a group of brain tumors known as gliomas, as they grow from a type of brain cell called a glial cell.
Diverse glioblastoma (GBM) tumors falling into several distinct methylation-based subgroups tend to share early driver mutations, which appear to have arisen long before individuals' initial GBM diagnoses and influence genetic features found in the tumors present at disease recurrence.
Scientists at the German Cancer Research Center (Heidelberg, Germany) and their colleagues performed whole-genome sequencing on tumor-matched blood sample controls from 21 GBM patients, along with RNA sequencing on primary and recurrent tumor samples. They also considered pairs of primary and recurrent tumors from 43 patients with IDH-wild type GBM that were profiled with targeted sequencing on 50 glioma-related genes, and used Illumina BeadChip arrays to assess DNA methylation levels across tumor samples from both groups.
The team found that by integrating these molecular data in phylogenetic and tumor growth, mutation, and evolution modeling, they were able to track down apparent initiating mutations involving chromosome 7 gains or chromosome 9 and 10 losses that appeared an estimated two to seven years before the patients' GBM diagnoses, along with mutations affecting the telomerase reverse transcriptase (TERT) promoter that appeared to mark tumor transitions to a rapid growth phase.
The authors suggested that their findings imply that standard therapy exerted little selective pressure on most recurrent tumors since the vast majority of driver mutations were acquired prior to initial diagnosis and only few drivers were acquired after initial treatment. Relapsed tumors acquired no stereotypical pattern of mutations and typically regrew from oligoclonal origins, suggesting sparse selective pressure by therapeutic measures. The study was published on March 21, 2019, in the journal Cancer Cell.
Related Links:
German Cancer Research Center
Diverse glioblastoma (GBM) tumors falling into several distinct methylation-based subgroups tend to share early driver mutations, which appear to have arisen long before individuals' initial GBM diagnoses and influence genetic features found in the tumors present at disease recurrence.
Scientists at the German Cancer Research Center (Heidelberg, Germany) and their colleagues performed whole-genome sequencing on tumor-matched blood sample controls from 21 GBM patients, along with RNA sequencing on primary and recurrent tumor samples. They also considered pairs of primary and recurrent tumors from 43 patients with IDH-wild type GBM that were profiled with targeted sequencing on 50 glioma-related genes, and used Illumina BeadChip arrays to assess DNA methylation levels across tumor samples from both groups.
The team found that by integrating these molecular data in phylogenetic and tumor growth, mutation, and evolution modeling, they were able to track down apparent initiating mutations involving chromosome 7 gains or chromosome 9 and 10 losses that appeared an estimated two to seven years before the patients' GBM diagnoses, along with mutations affecting the telomerase reverse transcriptase (TERT) promoter that appeared to mark tumor transitions to a rapid growth phase.
The authors suggested that their findings imply that standard therapy exerted little selective pressure on most recurrent tumors since the vast majority of driver mutations were acquired prior to initial diagnosis and only few drivers were acquired after initial treatment. Relapsed tumors acquired no stereotypical pattern of mutations and typically regrew from oligoclonal origins, suggesting sparse selective pressure by therapeutic measures. The study was published on March 21, 2019, in the journal Cancer Cell.
Related Links:
German Cancer Research Center
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans